Xtant Medical (NYSEAMERICAN:XTNT) Announces Quarterly Earnings Results, Meets Expectations

Xtant Medical (NYSEAMERICAN:XTNT) announced its earnings results on Wednesday. The medical device company reported ($0.02) earnings per share for the quarter, hitting the consensus estimate of ($0.02), FiscalAI reports. The company had revenue of $20.88 million during the quarter, compared to analyst estimates of $20.16 million. Xtant Medical had a net margin of 3.71% and a return on equity of 10.27%.

Here are the key takeaways from Xtant Medical’s conference call:

• Xtant raised its full-year 2026 revenue guidance to $101 million to $105 million, citing the addition of HEMOBLAST, recent product launches, and expanded sales coverage.
• The company secured exclusive U.S. distribution rights to HEMOBLAST Bellows, giving it entry into an estimated $2 billion hemostatic products market and broadening its biologics portfolio.
• Proceeds from the Companion Spine divestiture were used to strengthen the balance sheet, with Xtant reducing total indebtedness by $13.3 million in the quarter and increasing revolver availability.
• First-quarter revenue was $20.9 million, down from the prior-year period on a pro forma basis, mainly due to headwinds in amnio products tied to the advanced wound care market and the loss of non-recurring license revenue.
• Gross margin fell to 57.3% from 61.5% last year, and the company said the decline reflected the end of Q-code license revenue plus some product-mix pressure and excess inventory charges.

Xtant Medical Stock Up 0.4%

Shares of XTNT traded up $0.00 during mid-day trading on Thursday, hitting $0.48. 103,358 shares of the company’s stock were exchanged, compared to its average volume of 158,622. The stock’s 50-day moving average is $0.55 and its 200-day moving average is $0.63. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.63 and a current ratio of 2.65. Xtant Medical has a fifty-two week low of $0.44 and a fifty-two week high of $0.95. The company has a market cap of $67.53 million, a price-to-earnings ratio of 16.08 and a beta of -0.11.

Wall Street Analysts Forecast Growth

XTNT has been the subject of a number of research analyst reports. Craig Hallum reaffirmed a “buy” rating on shares of Xtant Medical in a research report on Wednesday, March 18th. BTIG Research restated a “buy” rating and set a $1.00 price target on shares of Xtant Medical in a research note on Wednesday. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $1.00.

Institutional Investors Weigh In On Xtant Medical

Several large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new position in Xtant Medical in the 2nd quarter valued at approximately $26,000. Mink Brook Asset Management LLC increased its position in shares of Xtant Medical by 125.8% during the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock worth $81,000 after acquiring an additional 60,997 shares during the period. Wiregrass Investment Management LLC acquired a new stake in shares of Xtant Medical in the fourth quarter valued at $81,000. Vanguard Group Inc. raised its stake in shares of Xtant Medical by 4.6% in the third quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock valued at $1,529,000 after acquiring an additional 104,159 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Xtant Medical by 28.8% in the fourth quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock valued at $721,000 after purchasing an additional 205,945 shares during the period. 69.33% of the stock is owned by hedge funds and other institutional investors.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.